Curcumin-Based Niche Solutions for High-Impact Environments
Legal Citation
Summary of the Inventive Concept
Adapting curcumin compositions as neurokinin 3 receptor antagonists for specialized, high-stakes applications, including disaster relief, high-security environments, and extreme weather conditions.
Background and Problem Solved
The original patent disclosed curcumin compositions as neurokinin 3 receptor antagonists, but it did not address the limitations of using these compositions in extreme or high-security environments. The new inventive concept addresses this gap by adapting the curcumin compositions for use in disaster relief, high-security environments, and extreme weather conditions, thereby expanding their applicability and potential impact.
Detailed Description of the Inventive Concept
The new inventive concept involves adapting curcumin compositions to address specific challenges in high-impact environments. For example, a system for disaster relief may comprise a curcumin composition and a delivery vehicle adapted for aerial deployment in extreme weather conditions. Alternatively, a method for providing neurokinin 3 receptor antagonist therapy in high-security environments may involve administering a curcumin composition to an individual in need thereof. The curcumin-based composition may be formulated with a synergistic ratio of curcumin to green tea extract to phycocyanin of about 5:2:1, suitable for use in emergency response kits.
Novelty and Inventive Step
The new inventive concept introduces novel and non-obvious adaptations of curcumin compositions for use in high-impact environments, which are not anticipated by the original patent. The inventive step lies in recognizing the potential of curcumin compositions in these specialized contexts and developing tailored solutions to address the unique challenges and constraints of these environments.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept may include adapting curcumin compositions for use in remote medical treatment, telemedicine platforms, or portable kits for extreme environments. Variations may include different synergistic ratios of curcumin to green tea extract to phycocyanin, or alternative delivery vehicles and formulations.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the fields of disaster relief, high-security environments, and extreme weather conditions. Target industries may include emergency response services, government agencies, and private companies operating in high-risk environments.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K36/9066 |
| A | A61 | A61K31/26 |
| A | A61 | A61K36/82 |
| A | A61 | A61P15/12 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical compositions and neurokinin receptor antagonist therapies, with expertise in natural compound formulations, drug delivery systems, and medical treatment methodologies
Person of Ordinary Skill (PHOSITA) Profile
A pharmaceutical researcher or clinical pharmacologist with advanced degrees in biochemistry or pharmacology, experienced in natural compound extraction, formulation optimization, and therapeutic application development
Obviousness Rationale
A person skilled in the art would recognize the inherent adaptability of curcumin-based compositions for specialized medical applications by leveraging the foundational teachings of the source patent. The disclosed variations represent predictable extensions of known neurokinin 3 receptor antagonist technologies, utilizing standard pharmaceutical engineering techniques to modify delivery mechanisms and application contexts. The PTD's proposed adaptations follow logical design progression from the original compositional framework, demonstrating incremental innovation rather than non-obvious invention.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,594 |
|---|---|
| Title | Curcumin compositions and methods of use as an NK3 antagonist |
| Assignee(s) | JDS Therapeutics, LLC |